Review

The IL-23/IL-17 axis in psoriatic arthritis

Erika Suzuki a, Elizabeth D. Mellins b, M. Eric Gershwin a, Frank O. Nestle c, Iannis E. Adamopoulos a,d,⁎

a Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA 95616, USA
b Divisions of Human Gene Therapy and Pediatric Rheumatology, Program in Immunology, Stanford University, Palo Alto, CA 94305, USA
c St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London School of Medicine, Guy's Hospital, London, United Kingdom
d Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children Northern California, CA 95817, USA

A R T I C L E   I N F O

Article history:
Received 7 October 2013
Accepted 13 November 2013
Available online xxxx

Keywords:
IL-17
IL-23
Psoriatic arthritis
NF-κB

A B S T R A C T

Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease, affecting both the skin and joints. Disease progression is associated with aberrant cytokine expression, and TNF blockade is the most successful therapy to date. However, not all patients are responsive to anti-TNF treatment, highlighting the need to better understand the cellular and molecular mechanisms that govern the disease. PsA associations with single nucleotide polymorphisms in IL23R as well as TRAF3IP2 (Act1), a molecule downstream of the IL-17 receptor (IL-17R), have linked the IL-23/IL-17 axis to disease pathology. Although both cytokines are implicated in PsA, a full picture of their cellular targets and pathogenic mechanisms has not yet emerged. In this review, we focus on the IL-23/IL-17 axis-elicited responses mediated by osteoclasts, keratinocytes and neutrophils. Expanding our understanding of the cellular and molecular mechanisms that dictate pathogenicity in PsA will contribute to developing novel treatment strategies to combat disease.

© 2014 Elsevier B.V. All rights reserved.

Contents

1. Introduction .................................................................................. 0
2. Molecular pathways in PsA pathogenesis .................................. 0
   2.1. IL-23 and IL-23 receptor ...................................................... 0
   2.2. IL-17 and IL-17 receptor ..................................................... 0
   2.3. RANKL and RANK receptor ............................................... 0
   2.4. NF-κB pathways ............................................................... 0
3. Cellular mechanisms in PsA pathogenesis ............................... 0
   3.1. Neutrophils ........................................................................ 0
   3.2. Osteoclasts ....................................................................... 0
   3.3. Cells in skin ....................................................................... 0
4. Conclusions .................................................................................. 0
   Disclosures ............................................................................... 0
   Take-home messages ................................................................... 0
   Acknowledgments ...................................................................... 0
   References ............................................................................... 0

1. Introduction

Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease affecting both the skin and joints in up to 1% of the worldwide population [1]. Psoriatic skin features commonly include epidermal hyperplasia (thickening of the epidermis), hyperkeratosis (thickening of the stratum corneum), parakeratosis (retention of nuclei in the stratum corneum), Munro's microabscesses (neutrophilic granulocytes in the epidermis) and mixed dermal infiltrates, including...
T cells, dendritic cells (DCs) and macrophages which together, lead to the clinical features of raised erythematous silvery plaques [23]. In addition to the skin, PsA targets the spine, the peripheral joints and the entheses (attachment sites of ligament to bone) [4]. PsA can lead to destructive bone loss, and 67% of PsA patients exhibit signs of erosive bone disease [1]. Peripheral enthesitis is a feature of a group of arthritides known as spondyloarthropathies, which include PsA, but is not commonly observed in other forms of arthritis, such as rheumatoid arthritis (RA) [5]. Other distinguishing features of PsA include elevated numbers of neutrophils and CD163+ macrophages in the synovium and the presence of typical psoriasis nail lesions, not observed in RA [1,6]. On the contrary, rheumatoid factor and anti-citrullinated peptide antibodies, which are commonly associated with RA, are not typically present in PsA [7,8]. Despite the differences, increased numbers of osteoclasts have been observed in PsA synovium, similar to RA, suggesting that some molecular mechanisms that contribute to its pathogenicity are shared across these types of inflammatory arthritis [9]. Since osteoclast activation can be achieved through IL-23 and IL-17 as reviewed in [10], it is plausible that the IL-23/IL-17 axis may govern distinct cellular and molecular mechanisms that contribute to bone erosion and epidermal hyperplasia, hallmark features of PsA.

A variety of genetic, immunological and environmental factors have been suggested to contribute to PsA pathogenesis [11]. Single nucleotide polymorphisms in IL23A, IL23R as well as TRAF3IP2 (Act1), a downstream target of the IL-17 receptor (IL-17R), confer susceptibility to PsA, implying a central role of the IL-23/IL-17 axis in PsA disease pathogenesis [12–14]. In this review, we will address the contribution of the IL-23/IL-17 axis to PsA, with a specific emphasis on the activation of osteoclasts, which are responsible for bone degradation, and of keratinocytes and neutrophils, which have been implicated in IL-23/IL-17-induced PsA pathology.

2. Molecular pathways in PsA pathogenesis

2.1. IL-23 and IL-23 receptor

IL-23 is a heterodimeric cytokine, composed of a p19 subunit and a p40 subunit; it binds IL-23R and IL-12Rβ1, the latter being shared with IL-12 [15]. The p40 subunit can act as a monomer, homodimer or as a heterodimer with p19, and both subunits are secreted predominantly by macrophages and DCs [15]. Genetically engineered IL-23R GFP reporter mice have confirmed that IL-23R is expressed on the surface of lymphoid cells, such as γδ T cells, innate lymphoid cells and cells of myeloid origin, including DCs, macrophages and monocytes [16]. The human IL-23R cytoplasmic domain has no inherent kinase activity yet contains seven tyrosine residues that can be phosphorylated to initiate downstream signaling [17]. Six of the seven human IL-23R tyrosine residues are conserved in mouse [17]. Three Src homology 2 domain (SH2) binding sites at Y399, Y484 and Y611 recruit SHP2 tyrosine phosphatase and signal transducer and activator of transcription (STAT)4, and STAT1 and STAT3, respectively [17]. Janus kinases, Jak2 and Tyk2, bind directly to IL-23R and IL-12Rβ1, respectively, and induce phosphorylation of their receptors and STAT3 to induce RORγ and RORα, both of which are encoded by the RORC gene to establish Th17-specific cell differentiation, as evidenced by increased gene expression of IL-17, IL-17F and IL-23R [17–19]. STAT3 regulates an isoform of RORγ, RORyt, and both STAT3 and RORyt bind the IL-17 promoter [20,21]. Binding of IL-23 to its receptor also stimulates the degradation of inhibitory subunit of nuclear factor kappa B alpha (IκBα) to induce activation of nuclear factor of kappa-light-chain-enhancer of activated B cells (NF-κB) [22] (Fig. 1).

2.2. IL-17 and IL-17 receptor

IL-17 (IL-17A) is a 15–20-kDa glycoprotein and a member of the IL-17 family of cytokines (IL-17, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F) [23]. Biologically active IL-17 is produced as a 35-kDa homodimer or heterodimer with IL-17F by γδ T cells, innate lymphoid cells including γδ T-cells, innate-like lymphoid cells, mast cells and neutrophils [24,25]. IL-17 binds IL-17R (IL-17RA/IL-17RC), which is expressed by various cells such as monocytes, lymphocytes, lymphoid tissue inducer cells, epithelial cells, synoviocytes, fibroblasts and keratinocytes [26,27] (Fig. 1).

IL-17RA and IL-17RC interact through specific SEFIR (similar expression to fibroblast growth factor genes and IL-17R) domains with the adaptor protein Act1 [28,29]. Act1 associates with inductive IκB kinase, IKK, which has been demonstrated to be indispensable for IL-17-induced neutrophilia [29]. Phosphorylation of Act1 (S311) leads to the formation of tumor necrosis factor receptor–associated factor (TRAF) 2–Act1 and TRAF5–Act1 complexes and stabilization of CXCL1 mRNA, a potent neutrophil chemokine [29]. In addition to TRAF2 and TRAF5, Act1 also binds TRAF6 to activate the NF-κB activator protein 1 (AP-1) or the CCAAT-enhancer–binding protein (C/EBP) cascade [30,31]. Independently of IKK, Act1 ubiquinates TRAF6 leading to the activation of NF-κB [32]. Moreover, NF-κB activity can be suppressed through TANK binding kinase 1 (TBK1) phosphorylation of Act1 on additional serine residues in both human (S162, S220, and S233) and mice (S147, S209, and S220) [33]. Thus, the IL-23/IL-17 axis influences activation of the NF-κB pathway in multiple ways.

The relevance of the IL-23/IL-17 axis in PsA is suggested by the elevation of IL-23p19/IL-23R and IL-17/IL-17R in psoriatic skin and synovial fluid from PsA patients [34–37]. Some findings in rodents argue that IL-17 was not required for IL-23-induced psoriatic-like disease, and IL-17 intradermal delivery failed to induce epidermal hyperplasia [38]. However, others using IL-17 deficient mice have demonstrated that IL-17 is a downstream mediator for IL-23-induced changes in murine skin, and IL-17 may represent an attractive therapeutic target in psoriatic patients [39]. In support of a prominent role of IL-17 in psoriasis, Cai et al., showed that absence of IL-17 signaling ameliorated IL-23-induced psoriatic-like features in mice [40]. Using an ex vivo human skin model, IL-17 failed to induce epidermal hyperplasia [41]. Collectively these data indicate that our understanding of the role of IL-17 in epidermal hyperplasia is incomplete, and it remains possible that IL-17 may have indirect effects on psoriatic pathology.

Neutralization of IL-23 signaling by antibodies and/or IL-23p19 gene ablation ameliorated collagen-induced arthritis (CIA), whereas overexpression of IL-23 induced arthritis with a severe bone destructive phenotype, independently of IL-17 [42–44]. However, neutralization of IL-17 signaling and gene ablation also demonstrated protection in the CIA model [45,46]. Therefore, IL-23 and IL-17 may exert effects in bone loss independent of each other and may induce bone resorption associated with PsA pathology by separate molecular mechanisms.

2.3. RANKL and RANK receptor

Receptor activator of nuclear factor kappa B ligand (RANKL) is a homotrimeric transmembrane protein expressed by bone-forming osteoblasts under physiological conditions; upon proteolytic cleavage or alternative splicing, RANKL is secreted as a soluble protein [47]. RANKL interacts with RANK, a homotrimeric transmembrane receptor expressed commonly on osteoclast precursors and DCs to induce their differentiation into multinucleated, bone-resorbing osteoclasts [48]. Upon binding RANKL, the RANK receptor recruits adaptor molecules, such as TRAF proteins (TRAF2, TRAF5 and TRAF6), to induce NF-κB and mitogen-activated kinases, such as Jun N-terminal kinase (JNK), nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) and AP-1 [49] (Fig. 1). Activation of these transcription factors leads to secretion of bone matrix degradation enzymes, including tartrate resistant acid phosphatase (TRAP), matrix metalloproteinase 9 (MMP9) and cathepsin K (CtK), which are central to the bone destruction process [50]. RANK is elevated in PsA synovial tissue, and both IL-23 and IL-17 up-regulate its expression [51–53]. IL-20, which is secreted by monocytes,
keratinocytes and Th17 cells, and IL-20R are also expressed in PsA and RA synovia and have been shown to upregulate RANK and RANKL [54–56]. IL-20 signaling via IL-20R2/IL-20R1 and IL-22R1/IL-20R2 receptor complexes also promotes keratinocyte proliferation and differentiation in psoriatic skin [57], and it may constitute an alternative pathway whereby the IL-23/17 axis indirectly promotes PsA pathology.

2.4. NF-κB pathways

There are five members of the NF-κB transcription factor family, including RelA (p65), RelB, c-Rel, NF-κB1 (p105) and NF-κB2 (p100). Three main pathways mediated by NF-κB include: 1) the canonical, 2) the p105 and 3) the alternative (p100) pathway, as reviewed in [58]. In the canonical pathway, phosphorylation of inhibitory IκB proteins (IκBα) leads to release of NF-κB (p50/p65 heterodimers) and its nuclear translocation to promote inflammation and cell survival [58]. The canonical pathway is dependent on phosphorylation of p105 proteins, leading to nuclear translocation of p52 heterodimers to promote inflammation. Unlike the canonical and p105 pathways, the alternative p100 pathway does not depend on the NF-κB essential modulator (NEMO)-IκKα–IκKβ) (NEMO-IKK) complex for phosphorylation, but rather NF-κB inducing kinase (NIK) and IκKα heterodimers phosphorylate p100 and allow nuclear translocation of p52/ReIβ heterodimers [58]. Mice deficient in both Nfkb1 (p105) and Nfkb2 (p100) demonstrate an absence of bone-resorbing osteoclasts [59]. In addition, p65 and RelB play important roles in osteoclast differentiation and survival [60,61]. Immediate early genes associated with NF-κB activation include TRAF6, NIK, and Src [58]. TRAF proteins involved in the canonical and alternative NF-κB pathways also regulate osteoclast differentiation, associated with RANK signaling [62]. IL-17R/Act1/TRAF6 activates the NF-κB pathway (Fig. 1) and regulates bone resorption [63,64].

Several studies have confirmed the presence of NF-κB activity in psoriatic (skin) disease [65], [66]. However, in a human study, elevated active p65 was not reduced to normal baseline levels by TNF blockade, suggesting that TNF-independent NF-κB activity is present in psoriatic pathology [67]. A role for NF-κB pathways in psoriasis and PsA is also implied by findings from genome-wide association scans (GWAS). These analyses revealed several susceptibility genes associated with NF-κB, including TNF induced protein 3 (TNFAIP3), TNIP1 (ABIN-1), TRAF3IP2, NFKB1 and REL (c-Rel) [14,68,12,69]. TNFAIP3 encodes an A20 cytoplasmic zinc finger protein, which induces degradation of NEMO to negatively regulate NF-κB [70]. Myeloid-specific A20 deficient mice exhibit sustained NF-κB activity and enhanced osteoclastogenesis, and A20 deficiency in keratinocytes allows hyperkeratosis but not differentiated psoriasis [71]. Although mice heterozygous for NEMO show skin abnormalities, they do not exhibit psoriatic-like disease, thus the significance of NEMO in psoriasis is unclear [72]. Another gene linked to
susceptibility to PsA is TNIP1 which encodes A20 binding and inhibitor of NF-κB-1 (ABIN-1). ABIN-1 expression is protective against psoriatic-like disease and regulates IL-17 and IL-22-producing T cells as well as IL-23 secretion from DCs [73].

Another susceptibility locus identified by GWAS is tumor necrosis factor receptor-associated factor 3-interacting protein interacting protein 2 (TRAF3IP2), which encodes Act1 [74]. Act1 deficient mice spontaneously develop skin inflammation and Act1-mediated signaling is required for the pathogenesis of CIA [75,76]. Therefore Act1 contributes to both skin inflammation and bone destruction, suggesting a plausible role for IL-17 in PsA [75,63].

3. Cellular mechanisms in PsA pathogenesis

3.1. Neutrophils

The induction of NF-κB activation by the IL-23/IL-17 axis results in the production of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage stimulating factor (GM-CSF), and various chemokines (CCL1, CCL2, CCL5 and CXCL8/IL-8) that in turn lead to the recruitment and migration of neutrophils [77–79]. IL-17 can stimulate endothelial expression of P-selectins, E-selectins and integrin ligands, including ICAM-1 and VCAM-1, to enhance neutrophil mobilization [80]. The presence of neutrophils in psoriasis typically correlates with increased IL-8 in psoriatic lesions, and IL-8 is also known to induce neutrophilia [41,81]. Furthermore, GM-CSF promotes myelopoiesis to generate monocytes and neutrophils [82,83]. Whether neutrophils respond directly to IL-17 remains controversial, as human neutrophils were recently shown to lack expression of IL-17RC [84]. A dense accumulation of neutrophils in the upper layers of psoriatic skin (stratum corneum) is commonly identified as Munro’s microabscess formation [85]. In mouse models of psoriatic-like disease, neutrophils are identified by their surface expression of CD11b and Gr-1low and neutrophil depletion using antibodies against Gr-1 reduces epidermal thickening and microabscess formation in flaky skin mice [86,87]. However, although neutrophils have been recognized to play a role in psoriatic disease pathogenesis, these cells have not been well characterized. New evidence suggests that neutrophils have a much longer lifespan than previously appreciated and have novel roles in regulating the pool size and function of hematopoietic cells in the bone marrow [88,89]. This suggests that neutrophils also may have the capacity to modulate hematopoietic precursors in tissues outside of the bone marrow microenvironment, potentially regulating cytokine-mediated inflammatory precursors in multiple organ systems during disease progression in inflammatory diseases, such as PsA. Thus, specific sub-populations of neutrophils may initiate or perpetuate PsA pathology.

3.2. Osteoclasts

Myeloid-derived cells differentiate into osteoclasts in the presence of macrophage colony stimulating factor (M-CSF) and RANKL. RANK and colony stimulating factor 1 receptor (CSF-1R/c-fms) are both expressed on osteoclast precursor cells that, upon stimulation with RANKL and M-CSF, develop into mature bone-resorbing cells [90,91]. In osteoclast precursors, activation of the RANKL–RANK pathway induces calcium oscillations that lead to calcineurin-mediated activation of NFATc1 [92]. NFATc1 regulates the expression of Oscar, CalcR, Igfb3, Rcan2, Myo1d, and Mst1r, and augments the expression of Mmp9, Acp5, Ctsk, Mmp14, and Clcn7, genes required for bone destruction [92,93]. Activator protein (AP)-1, a transcriptional regulator of c-fos, is also required for osteoclast differentiation and has been implicated in PsA [94]. Osteoclasts can be generated from RANKL, RANK or TRAF6 deficient mice suggesting that RANKL–RANK-independent osteoclast differentiation pathways also exist [64].

The IL-23/IL-17 axis plays a critical role in osteoclastogenesis via a number of direct and indirect effects that both positively and negatively modulate osteoclast formation. Evidence that IL-23 negatively regulates osteoclastogenesis comes from in vitro observations indicating indirect inhibition via T cells [95,96]. Conversely, IL-23-induced Th17 cell differentiation results in RANKL secretion and thus promotes osteoclastogenesis [97]. Yago and colleagues also demonstrated that IL-23 induces osteoclastogenesis via IL-17 in vitro [43]. In later experiments it was shown that IL-17 dose-dependently induced osteoclastogenesis in human PBMC in the absence of RANKL in a mechanism involving TNF [98]. Additionally, IL-17 upregulated CSF-1R and RANK and promoted osteoclast differentiation [53]. IL-17 also acts on osteoblasts to secrete RANKL to further enhance bone resorption [99]. IL-17 further modulates the expression of the osteoclast fusion protein, DC-STAMP (dendritic cell-specific transmembrane protein), a potential biomarker for early prognosis of PsA [100].

3.3. Cells in skin

Psoriatic skin disease is mediated primarily by immune cells and epidermal keratinocytes [101]. Various triggers of psoriatic disease have been suggested, including the formation of DNA and antimicrobial LL-37 complexes that promote activation of myeloid DCs and their migration to the draining lymph nodes, where they induce differentiation of naïve T cells into effector IL-17-producing cells [102]. Recently, innate lymphoid cells such as γδ T cells, an additional cellular source of IL-17, were shown to be elevated in psoriatic skin [103,40]. Under homeostatic conditions, γδ T cells and other innate-like lymphoid cells constitutively express IL-23R and the chemokine receptor CCR6, which mediate their recruitment to the skin to interact with keratinocytes and other immune cells [104]. RORγt expressing innate-like lymphocytes and Vγ4+ γδ T cells were shown to initiate Aldara-induced psoriatic-like disease in mice [25]. It is thought that the secretion of IL-17 and IL-22 from IL-23-stimulated cells promotes aberrant keratinocyte differentiation and hyperproliferation, forming the basis of epidermal acanthosis or diffuse hyperplasia, hyperkeratosis, parakeratosis and Munro’s microabscess formation typically observed in PsA [105,101]. These cytokines then activate keratinocytes via an autocrine or paracrine manner leading to secretion of antimicrobial peptides (e.g. LL-37, cathelicidin, β-defensins), chemokines (e.g. CXCL1, CXCL8), and S100 proteins (e.g. S100A7-9) to mediate inflammation in the skin [106] (Fig. 2). Psoriasis-like skin disease and arthritis was observed in mice with epidermal deletion of Jun proteins [107]. Interestingly, this model suggests that keratinocytes, through the JunB/AP-1 pathway, may underlie both psoriatic-like and arthritic features. However, subsequent reports showed that mRNA and protein levels of JunB are not reduced in human psoriatic plaques, questioning the significance of Jun proteins, at least in human psoriasis [108].

4. Conclusions

The role of IL-23 in inducing IL-17-producing T cells has been well studied; however, the importance of the IL-23/IL-17 axis in myeloid cell populations remains less understood. Nonetheless, sufficient progress has been made in understanding the role of the IL-23/IL-17 axis in psoriatic disease to support initiation of current clinical trials, which are evaluating the efficacy of IL-23 and IL-17 targeted therapy in psoriasis and PsA [109,110]. More research is required to identify the cellular and molecular mechanisms of IL-23/IL-17 action, which are only partly known [111]. Elucidating the underlying molecular mechanisms behind these therapeutic targets will help provide insights into PsA disease pathogenesis that can be exploited for the design of more effective treatment strategies.

Disclosures

No conflict of interest disclosed.
directly and further induce osteoclast formation and secretion of bone-degrading enzymes TRAP, CatK and MMP9 leading to bone destruction.

secreted by macrophages induces IL-17 from Th17 cells which has been demonstrated to act on osteoblasts (OB) to secrete RANKL. Th17 cells have also been shown to secrete RANKL together, these cellular networks promote epidermal hyperplasia and Munro’s microabscess formation. In the bone, IL-23 has been shown to upregulate RANK on preosteoclasts (pOC). IL-23 secreted by macrophages induces IL-17 from Th17 cells which has been demonstrated to act on osteoblasts (OB) to secrete RANKL. Th17 cells have also been shown to secrete RANKL directly and further induce osteoclast formation and secretion of bone-degrading enzymes TRAP, CatK and MMP9 leading to bone destruction.

Take-home messages

- Single nucleotide polymorphisms in IL23R as well as TRAF3IP2, a target downstream of the IL-17 receptor (IL-17R), have linked the IL-23/IL-17 axis to PsA pathology.
- The IL-23/IL-17 axis is a modulator of NF-κB activation in inflammation.
- NF-κB activation is directly linked with osteoclastogenesis and epidermal hyperplasia, hallmark features of PsA.

Acknowledgments

We thank Thanh Nguyen for the help with graphic design. Research reported in this publication was partly supported by the NIAMS/NIH AR62173 and Shriners Hospitals for Children SHC 250862 to IEA. ES is the recipient of a NCATS/NIH #UR1 TR000002 pre-doctoral fellowship. EDM is partly supported by NIH R01AR061297. FON is partly supported by: EU FP7 grant agreement HEALTH-F2-2011-261366 and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, SHC, NHS, NIHR or the Department of Health. We apologize to our colleagues for omissions imposed by space limitations.

References

The RANK-L and RANK: T cells, bone loss, and mammary gland involution


Please cite this article as: Suzuki E, et al, The IL-23/IL-17 axis in psoriatic arthritis, Autoimmun Rev (2014), http://dx.doi.org/10.1016/j.autrev.2014.01.050


